ReviewBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2026
[Development of the epidemiology of antibiotic-resistant pathogens in human medicine and their significance for the health system in Germany].
Review in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization (WHO) has ranked antibiotic resistance as one of the 10 biggest global threats, leading to significant morbidity, mortality, and economic burden. In Germany the developing resistance situation is critical. The resistance data of the most relevant drug-bug combinations are calculated with data from the German Antibiotic Resistance Surveillance (ARS) system. For four of these drug-bug combinations, incidence reduction targets for 2030 (bloodstream infections per 100,000 inhabitants) have been outlined in the German Antimicrobial Resistance Strategy (DART 2030) action plan. The incidence for the gram-positive vancomycin-resistant Enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) are currently within the target range. However, this is not the case for Escherichia coli with resistance to third generation Cephalosporins and Carbapenem-resistant Klebsiella pneumoniae, both of which are increasing in incidence. In an EU comparison, the incidence of AMR in Germany ranks in the middle.In addition to the resistance data and incidence, the Measuring Infectious Causes and Resistance Outcomes for Burden Estimation (MICROBE) project presents the absolute numbers of mortalities from infections with antimicrobial-resistant pathogens. In Germany, 40,000 deaths per year are associated with antibiotic-resistant infections, and in almost 10,000 of these cases the death was attributable to the antibiotic-resistant pathogen. This means that more people in Germany are dying from antibiotic-resistant infections than other infectious diseases.The effects on the healthcare system are substantial; the increasing antibiotic resistance in particular leads to greater burden of disease in haemato-oncological diseases and poses challenges to effective perioperative antibiotic prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.